Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2026 16:05 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Announces CEO Transition

BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
March 26, 2026 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

Virtual Event will feature Key Opinion Leaders (KOLs) Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR Cue Biopharma management and KOLs will discuss CUE-401, the company’s lead asset for the...
March 16, 2026 16:05 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness –CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseasesAppointed...
March 09, 2026 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026

BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
February 17, 2026 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases

In two non-GLP studies, CUE-401 was well tolerated with no adverse events observed Proof-of-concept studies reinforce promising preclinical profile and therapeutic potential of CUE-401 BOSTON,...
February 12, 2026 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer

BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
December 19, 2025 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Announces Pricing of $10 Million Public Offering

BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
December 18, 2025 16:02 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Announces Proposed Public Offering

BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
November 12, 2025 16:05 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15M...
November 06, 2025 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Exclusive collaboration and license agreement focuses on advancing novel T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the CUE-100 series of Immuno-STATs®Novel therapeutic...